Thesis
Scancell-Neuphoria merger bets $79M on iSCIB1+ beating an approved TIL therapy in post-checkpoint melanoma, if Phase 3 confirms the 77% PFS signal
A Scancell-Neuphoria all-share merger, funded to 2029, consolidates around iSCIB1+, an allogeneic cell therapy showing 77% progression-free survival at 22 months in advanced melanoma patients who have failed checkpoint inhibitors. The program competes directly against Iovance's approved autologous TIL therapy lifileucel in the same post-anti-PD-1 population, and the thesis resolves on whether Phase 3 confirms that PFS signal with a survival benefit. The Merck-partnered small molecule failure in Alzheimer's and the earlier BNC-210 Phase 3 miss in social anxiety disorder have stripped the company to a single unproven registrational bet.
Focus
Further Phase 2 SCOPE data readout for iSCIB1+
next 12 months
Bull
A positive outcome would see mature PFS data holding at or above the 77% landmark with emerging overall survival trends that compare favorably to Amtagvi (lifileucel) benchmarks in the post-anti-PD-1 melanoma population. This would de-risk the Phase 3 design, potentially attract partnership interest, and support the combined company's Nasdaq debut with clinical momentum — reinforcing that the merger premium is justified.
Bear
The most likely failure modes are PFS curve decay as follow-up matures, bringing the landmark estimate down toward conventional second-line benchmarks, or an immature overall survival dataset that fails to show a directional signal. Small Phase 2 sample sizes make the 77% figure susceptible to statistical noise, and any evidence of patient selection bias in the SCOPE enrollment would substantially erode confidence in Phase 3 success.
Unlock the full thesis for NEUP.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.